@article{article, title  = {{Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial}},

 publisher = {{Elsevier BV}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/217236 }},

 year = {{2024}},

 month = {{9}},

 author = {{Cook G and Ashcroft AJ and Senior E and Olivier C and Hockaday A and Richards J and Cavenagh JD and Snowden JA and Drayson MT and de Tute R and Roberts L et al}},

 doi = {{10.1016/s2352-3026(24)00249-7}},

 volume = {{11}},

 journal = {{The Lancet Haematology}},

 issue = {{11}},

 pages = {{e816-e829}},

 note = {{Accessed on 2025/11/15}}}